All resolutions were approved at the Annual General Meeting of SGS, including the re-election of Calvin Grieder to Chairman of the Board and election of Ms. Janet S. Vergis to the Board of Directors.

  • All proposals of the Board of Directors approved
  • Calvin Grieder was re-elected to the Board of Directors and as Chairman of the Board of Directors; all other Board members standing for re-election confirmed
  • Ms. Janet S. Vergis joined the SGS Board as an independent member
  • Messrs François von Finck, Gérard Lamarche and Cornelius Grupp did not stand for re-election
  • PricewaterhouseCoopers SA, Geneva, was elected as Auditors of SGS SA and Group Auditors for the business year 2021

Due to public health regulations restricting public gatherings, our Annual General Meeting took place on March 23 without the physical attendance of shareholders, who received prior communication to this effect.

The Management Report, the Financial Statements and the Consolidated Financial Statements for 2020 were approved. All proposals for the remuneration report were approved by shareholders.

Shareholders approved the proposed appropriation of available earnings and approved the dividend for the past financial year to CHF 80 per share.

The election of Ms. Janet S. Vergis as a new independent Board member was also announced today. Ms. Vergis brings over 30 years of experience in positions of responsibility in research & development, new product development and sales & marketing in the healthcare industry and has served as a member of company management boards for over a decade. From 2013 to 2019 she served as an executive advisor to various private equity firms, including Warburg Pincus, Deerfield Mgmt., Water Street Healthcare Partners and Vatera Healthcare Partners.

From 2011 to 2012, as the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company, she led the turnaround of the business and its subsequent successful sale. Prior to joining OraPharma, Ms. Vergis managed a multi-billion portfolio at Johnson & Johnson (NYSE: JNJ) as President of Janssen Pharmaceutica, McNeil Pediatrics and Ortho-McNeil Neurologics, contributing to several Johnson & Johnson companies during her career. She has also served on the boards of MedDay Pharmaceuticals, Amneal Pharmaceutical (NYSE:AMRX), Lumara Health and OraPharma, Inc.

All other Board members who stood for re-election were confirmed for a term of one year ending on the date of the 2022 Annual General Meeting:

  • Mr. Calvin Grieder (Chairman)
  • Mr. Sami Atiya
  • Mr. Paul Desmarais, jr.
  • Mr. Ian Gallienne
  • Mr. Shelby R. du Pasquier
  • Ms. Kory Sorenson
  • Mr. Tobias Hartmann

Shareholders also approved the 2020 Remuneration Report and, as required by Swiss law on Say on Pay, approved the remuneration of the Board until the next Annual Shareholders Meeting, the variable compensation of the Senior Management team in relation to the 2020 performance, granted a maximum envelope for the fixed remuneration of the management team for the year 2022 and authorized the issuance of a new Long Term Incentive Plan for a vesting period of three years.

For further information, please contact:

Investors: Toby Reeks
SVP Corporate Communication, Sustainability & Investor Relations
t: +41 79 641 83 02

About SGS

SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 89,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.